April 6, 2017
Sosei Group said on April 5 that its wholly owned UK subsidiary Heptares Therapeutics is now eligible to receive a milestone payment of US$12 million for its immuno-oncology candidate AZD4635 after the successful completion of a preclinical program. AZD4635 is...read more